ClinicalTrials.gg
RecruitingNCT06792019Updated Aug 15, 2025

Study of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness

A Phase 1/2 interventional study of CM313(SC) injection-low dose and CM313(SC) injection-high dose in Platelet Transfusion Refractoriness, sponsored by Keymed Biosciences Co.Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-15.

Sponsored by Keymed Biosciences Co.Ltd · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a randomized, open-label, phase IB/II clinical study to evaluate the safety and preliminary efficacy of CM313(SC) injection in patients with Platelet Transfusion Refractoriness.

02

Conditions studied

  • Platelet Transfusion Refractoriness
03

In context

Lead sponsor

Keymed Biosciences Co.Ltd is the lead sponsor of 68 studies on the registry; 34 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Thrombocytopenia dependent on transfusions and diagnosed with platelet transfusion refractoriness.
  2. Presence of one or more kinds of antiplatelet antibodies.
  3. Male or female, age≥18 years.
  4. The (ECOG) physical status score ≤2.
  5. Willing and able to comply with the requirements for this study and written .

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed with Idiopathic thrombocytopenic purpura.
  2. transfusion refractoriness caused by non-immune factors.
  3. Previously treated with the anti-CD38 monoclonal antibody.
  4. Have an allergy to humanized monoclonal antibody or any part of CM313.
  5. Pregnant or breastfeeding females, or females planning to become pregnant during the study.
  6. Any condition considered to be ineligible for the study by the investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    CM313(SC)(low dose group)

    Biological: CM313(SC) injection-low dose

  • Experimental
    CM313(SC)(high dose group)

    Biological: CM313(SC) injection-high dose

Interventions

  • Phase IB:CM313(SC) administered at low dose according to the protocol. Phase II:CM313(SC) administered at different doses based on Phase IB's results.

  • Phase IB:CM313(SC) administered at high dose according to the protocol. Phase II:CM313(SC) administered at different doses based on Phase IB's results.

06

What researchers measure

Primary outcomes

  1. Adverse events (AE)

    Assess the safety of CM313(SC) injection

    Time frame: Up to 24 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Nov 2027, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2025
First posted
Jan 24, 2025
StartActual
Mar 25, 2025
Primary completionEst.
Nov 16, 2027
CompletionEst.
Nov 16, 2027
Last update
Aug 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06792019
Responsible party
Sponsor
First posted
Jan 24, 2025
Start date
Mar 25, 2025
Primary completion
Nov 16, 2027 (estimated)
Completion
Nov 16, 2027 (estimated)
Last update
Aug 15, 2025

Study contacts

Qian Jia
Contact
qianjia@keymedbio.com
028-88610620
Jun Shi
principal investigator · Institute of Hematology & Blood Diseases Hospital, China

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lumrotatug

Start the discussion